Marked thrombocytosis during treatment with ceftazidime for pulmonary infection

Chen, Huang‐Chi; Wang, Chengyuan; Wang, Chuansheng

doi:10.1007/s11096-007-9145-8

Cited by 10 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the correlation coefficient for thrombocytosis versus bone metastasis was weak. Possible explanations for the weakness of this correlation include the following: i) Reactive thrombocytosis may have been induced by a number of other factors, such as infection, rheumatic autoimmune disease and coronary heart disease ( 30 , 31 ); b) relevant data may not have been recorded during follow-up; c) thrombocytosis may only correlate with one type of bone metastasis (osteoblastic, osteolytic or mixed) ( 32 ); and d) the small sample size may have effected the sampling error and therefore the overall findings of the study.…”

Section: Discussionmentioning

confidence: 99%

Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients

Zhang

Huang

et al. 2014

Oncology Letters

View full text Add to dashboard Cite

Thrombocytosis is commonly observed in patients exhibiting a variety of malignancies, including pulmonary, gastrointestinal and hepatic cancer. In the present study, the correlation between distant metastasis and thrombocytosis was retrospectively reviewed in 308 cases of histopathologically confirmed pulmonary adenocarcinoma. The patients were classified as having thrombocytosis or not, based on their platelet counts upon diagnosis; thrombocytosis was documented in 82/308 patients (26.6%). A log-rank test indicated a statistically significant difference in survival between patients exhibiting thrombocytosis compared with patients not exhibiting thrombocytosis (P<0.001). In addition, the occurrence of distant metastasis and the survival period were correlated with the presence of thrombocytosis upon diagnosis. In descending order of frequency, metastases were documented at the following sites: Lymph nodes (218/308 patients; 70.8%), bone (138/308 patients; 44.8%), lung (93/308 patients; 30.2%), brain (67/308 patients; 21.8%), liver (46/308 patients; 4.9%), adrenal glands (11/308 patients; 3.6%) and kidneys (5/308 patients; 1.6%). Bone metastasis occurred significantly more frequently in patients exhibiting thrombocytosis (50/82 patients: 61.0%; P<0.05) compared with patients not exhibiting thrombocytosis (88/226 patients; 38.9%). Furthermore, according to univariate analysis, thrombocytosis, weight loss, an Eastern Cooperative Oncology Group performance status score of ≥2 points, anemia, increased erythrocyte sedimentation rate, and increased alkaline phosphatase (AKP) and carcinoembryonic protein (CEA) levels were risk factors for bone metastasis. According to multivariate analysis, thrombocytosis, weight loss, and increased AKP and CEA levels were correlated with bone metastasis. Therefore, patients exhibiting pulmonary adenocarcinoma and thrombocytosis have a higher risk of bone metastasis compared with patients not exhibiting thrombocytosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients

Zhang

Huang

et al. 2014

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…The diagnosis of thrombocytosis induced by drugs is challenging in the presence of other diseases. The cases that developed thrombocytosis due to drugs such as G-CSF, betalactam antibiotics, miconazole, vinca alkaloids, iron therapy, enoxaparin, antipsychotic drugs, adrenaline, glucocorticoids, retinoic acid, ciprofloxacin have been reported [7][8][9][10][11][12]. Mechanisms such as elevation of endogenous IL-6, other cytokines or catecholamines, increased megakaryocytes, increased splenic mobilization, prolonged platelet life-span have been suggested in the etiopathogenesis of ST [9].…”

Section: Discussionmentioning

confidence: 99%

Thrombocytosis Development due to the Use of Methotrexate in a Patient with Rheumatoid Arthritis

Kaydok¹,

Salbaş²

2018

Rheumatology

View full text Add to dashboard Cite

Rheumatoid arthritis is a systemic rheumatic disease that affects various organs and systems. In the course of rheumatoid arthritis, various blood disorders including thrombocytosis (>400.000/mm 3 ), an increase in the platelet count are observed. Methotrexate is a disease-modifying agent used in the treatment of Rheumatoid Arthritis and various rheumatic diseases. During methotrexate treatment, hematologic problems such as leukopenia, anemia, and thrombocytopenia are observed generally due to bone marrow suppression. In our case report, we aimed to present a 56 year-old patient who has arthritis of both hands and was diagnosed with rheumatoid arthritis and whose platelet values were initially within normal limits and then increased up to the level of 808.000/microliter despite a clinical and laboratory suppression in the disease activity after the initiation of methotrexate treatment, and quickly returned to normal values after the termination of methotrexate treatment. In conclusion, we think that the response of the blood profile to drugs may be very different, as in our case, and therefore, patients should be carefully monitored.

show abstract

“…15 To improve the application of the data to the Naranjo probability scale, adaptations were made by adding thrombocytosis-specific criteria to improve the grading of case reports for causality, as seen in Table 2. For the purpose of this review, reports of suspected thrombocytosis were systematically assessed for causality (Table 3 16-45 ). The following criteria will be utilized to assess causality of a drug by case report: number of cases described by independent investigators and the Naranjo score associated with causality.…”

Section: Methodsmentioning

confidence: 99%

“…A significant number of antibiotics have been implicated in the development of thrombocytosis. [18][19][20][21]26,34,39,44 We have identified 10 cases of thrombocytosis attributed to antibiotics, from 8 different investigators with at least 1 case >5 on the Naranjo assessment score. This is good evidence that, as a class, antibiotics would be considered causative in the development of thrombocytosis.…”

Section: Antibioticsmentioning

confidence: 99%

A Review and Assessment of Drug-Induced Thrombocytosis

Thompson

2018

Ann Pharmacother

View full text Add to dashboard Cite

Objectives: The purpose of this article is to review the current literature on drug-induced thrombocytosis with the goal of critically assessing causality and providing a comprehensive review of the topic. Thrombopoietic growth factors, such as thrombopoietin-receptor agonists (romiplostim and eltrombopag) and erythropoietin are not included in our review. Data Sources: The literature search included published articles limited to the English language and humans in MEDLINE, EMBASE, and Web of Science databases. MEDLINE/PubMed (1966 to September 2018) was searched using the MeSH terms thrombocytosis/chemically-induced and thrombocytosis/etiology. EMBASE (1980 to September 2018) was searched using the EMTAGS thrombocytosis/side effect. Web of Science (1970 to September 2018) was searched using the search term thrombocytosis. References of all relevant articles were reviewed for additional citations and information. Study Selection and Data Extraction: Review articles, clinical trials, background data, case series, and case reports of drug-induced thrombocytosis were collected, and case reports were assessed for causality using a modified Naranjo nomogram. Data Synthesis: Drug-induced thrombocytosis, a form of reactive thrombocytosis cannot be easily differentiated from more common etiologies of reactive thrombocytosis. In all, 43 case reports of drug-induced thrombocytosis from a wide variety of drugs and drug classes were reviewed using a modified Naranjo probability scale that included criteria specific for thrombocytosis. Conclusions: Drug-induced thrombocytosis is a relatively rare adverse drug reaction. The strongest evidence of causality supports low-molecular-weight heparins and neonatal drug withdrawal. Weaker evidence exists for all-trans retinoic acid, antibiotics, clozapine, epinephrine, gemcitabine, and vinca alkaloids.

show abstract

Marked thrombocytosis during treatment with ceftazidime for pulmonary infection

Cited by 10 publications

References 9 publications

Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients

Correlation between bone metastasis and thrombocytosis in pulmonary adenocarcinoma patients

Thrombocytosis Development due to the Use of Methotrexate in a Patient with Rheumatoid Arthritis

A Review and Assessment of Drug-Induced Thrombocytosis

Contact Info

Product

Resources

About